ReviewCurrent diabetes reviews2026
Circulating Biomarkers as a Window into the Relationship between Sarcopenia and Diabetes: Implications for Effective Management.
Review in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
aimsThis study aims to investigate the relationship between sarcopenia and circulating biomarkers in diabetes, with a focus on early detection and effective management strategies.
methodsA literature review was conducted using the ScienceDirect, Scopus, PubMed, and Web of Science databases up to December 2024. Key search terms included "diabetes," "sarcopenia," "HbA1c", "glucose," "insulin," and specific biomarkers such as inflammatory markers, adipokines, and myokines. RESULTS AND DISCUSSION: Aging is associated with a decline in organ and bodily system functionality, with sarcopenia being particularly prominent due to its progressive loss of muscle mass and function. This condition increases health risks and mortality in the elderly. Muscles, as the primary consumers of glucose, play a crucial role in glucose uptake; reduced mass can exacerbate insulin resistance. Sarcopenia and diabetes share common pathophysiological mechanisms, including insulin resistance, inflammation, and vascular complications. Circulating biomarkers, crucial for diabetes management, may offer insights into the early stages of sarcopenia.
conclusionThe complex relationship between sarcopenia and diabetes, influenced by shared pathophysiological pathways, presents challenges in geriatric healthcare. Circulating biomarkers hold promise for early detection and monitoring of sarcopenia, potentially enhancing patient outcomes and quality of life. Further research is necessary to validate these connections and develop targeted treatments for individuals affected by these conditions.
Indexed as
Identifiers
39949094What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.